SAGE Therapeutics Inc at SVB Leerink CNS Forum (Virtual) Transcript
All right. Thanks, everyone, for joining us for our last session of day 1 of the SVB Leerink CNS Forum. We are very thankful and lucky to have Sage Therapeutics' management team here. The topic is addressing key areas of debate regarding all data. And we have Barry Greene, CEO; and Steve Kanes, the CMO. And so the goal here is to kind of do a little bit of a fireside chat, Q&A and hit some of the key issues. And so please if we're not hitting the issues that you want to hit, please send us an email, let me know, and I'll try to get the questions asked.
Questions & Answers
So I'll just kick it right off and just jump right into it, guys, and just say, look, number one, a key criticism of the data is that you over the powered the study such that the study with stat-sig, but not clinically meaningful. And what are your thoughts about that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
